SCHEMBL20122946

SCHEMBL20122946

COc1ccc(-c2cc(Cl)cc3c2[nH]c2cnccc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CHUK O15111 17/20 0.61
ICOSLG O75144 5/20 0.61
ICOS Q9Y6W8 5/20 0.61
GCGR P47871 1/20 0.46
MAPK14 Q16539 1/20 0.46
DYRK1A Q13627 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664138 1.00 CHUK (0.61) CHUKICOSLGICOSGCGRMAPK14
SCHEMBL30664253 0.85 CHUK (0.55) CHUKICOSLGICOS
SCHEMBL20122970 0.85 CHUK (0.55) CHUKICOSLGICOS
SCHEMBL20122900 0.81 CHUK (0.65) CHUKICOSLGICOS
SCHEMBL30664284 0.81 CHUK (0.65) CHUKICOSLGICOS
SCHEMBL30664350 0.81 CHUK (0.58) CHUKICOSLGICOS
SCHEMBL20122974 0.81 CHUK (0.58) CHUKICOSLGICOS
SCHEMBL30664319 0.80 CHUK (0.60) CHUKICOSLGICOS
SCHEMBL20122971 0.80 CHUK (0.60) CHUKICOSLGICOS
SCHEMBL20122797 0.78 MAOA (0.54) CHUKICOSLGICOSGCGRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 CHUK 1582/4885ICOSLG 906/4885ICOS 1550/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 CHUK 1582/4885ICOSLG 906/4885ICOS 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.